Objectives: The aim of this studi to prove the angiogenic agent such as Vascular Endothelial Growth Factor (VEGF)-A, Interleukin (il)-6 and Mast cell had role to promote aggresivieness of BCC.
Knowing the increased expression of angiogenic agents will be able to provide optimal treatment options for BCC patients, thereby increasing the quality of life of patients.
Introduction: Basal Cell Carcinoma (BCC) is a non-melanoma skin cancer originating from the basal layer of the epidermis and non keratinized cell. BCC is locally invasive, aggressive and destructive, but very rarely do metastase. Basal cell carcinoma (BCC) is a very common malignant skin tumor that rarely metastasizes, even though is often locally aggressive. Several factors, like a large size (more than 3 cm), face localization, exposure to ultraviolet rays, histological variants, infiltration level and perineural or perivascular invasion, are associated with a more aggressive clinical course.
Materials / method: Archived specimens from 19 cases diagnosed with primary BCC were collected from July 2018 to October 2018 at the Dr. Moewardi Public Hospital in Surakarta, Central Java, Indonesia. Clinical findings such as age, gender and tumor localization were obtained from medical records. Histopathological types of BCC were determined and histopathological classification of the lesions was performed according to the criteria proposed by Dixon and Jacobs et al. The specimens was examined by immunohistochemistry on VEGF-A, Il-6 expression and Mast cell spesific histological staining.
Results: In A BCC there was a 14-fold VEGF-A expression compared to NA BCC on +3 scoring. Based on the VEGF-A expression, the results were significant with the aggressiveness of BCC (p <0.05) so that there were differences in VEGF-A expression in A BCC and NA BCC. Mast cell expression in all BCC subtypes with varying values. The highest number of mast cells is found in micronodular BCC subtypes. Il-6 expression was found to be positive in 15 samples (78.96%) of overall BCC, there was a significant relationship between Il-6 expression and BCC subtype.(p <0.05).
Conclusion: An increase in angiogenic agent can be a sign of BCC in the nature of aggressiveness so that it becomes a consideration in the management of BCC, thereby reducing the risk of recurrence, invasive and destructive properties in the surrounding tissue so as to improve the patient's quality of life. The importance of find out angiogenic agent expressions such as VEGF-A, mast cells and IL-6 before administering BCC.
Declaraciones
¿Ha recibido algún tipo de financiamiento para realizar su investigación sobre esta temática?
Si
Por favor especifique las entidades (individuo, empresa, sociedad): Funding assistance from the Department of Education and Research at the Moewardi Public Hospital Surakarta Central Java Indonesia
¿Ha recibido algún pago, honorario u otra compensación por su trabajo acerca de esta investigación?
Si
Por favor especifique las entidades (individuo, empresa, sociedad): Funding assistance from the Department of Education and Research at the Moewardi Public Hospital Surakarta Central Java Indonesia
¿Tiene vínculos financieros con alguna entidad que podría llegar a competir estrechamente con los medicamentos, materiales o instrumentos tratados en su investigación?
No
¿Posee o ha solicitado una patente relacionada a los materiales, productos o instrumentos utilizados en su investigación?
No
Este trabajo es presentado gracias al apoyo de: Director of Dr. Moewardi Public Hospital in Surakarta Central Java Indonesia
